Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Harvard Business School
Accenture
Deloitte
Colorcon
Teva
Federal Trade Commission
Fish and Richardson
QuintilesIMS

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208159

« Back to Dashboard

NDA 208159 describes VISTOGARD, which is a drug marketed by Wellstat Therap and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the VISTOGARD profile page.

The generic ingredient in VISTOGARD is uridine triacetate. There are thirty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the uridine triacetate profile page.
Summary for 208159
Tradename:VISTOGARD
Applicant:Wellstat Therap
Ingredient:uridine triacetate
Patents:2
Formulation / Manufacturing:see details
Pharmacology for NDA: 208159
Suppliers and Packaging for NDA: 208159
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VISTOGARD uridine triacetate GRANULE;ORAL 208159 NDA Wellstat Therapeutics Corporation 69468-151 N 69468-151-04
VISTOGARD uridine triacetate GRANULE;ORAL 208159 NDA Wellstat Therapeutics Corporation 69468-151 N 69468-151-10

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:GRANULE;ORALStrength10GM/PACKET
Approval Date:Dec 11, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 11, 2022
Regulatory Exclusivity Use:EMERGENCY TX OF PTS FOLLOWING A FU OR CAPECITABINE OD, OR WHO EXHIBIT EARLY-ONSET, SEVERE OR LIFE-THREATENING TOXICITY AFFECTING THE CARDIAC SYSTEM OR CNS, AND/OR EARLY-ONSET, UNUSUALLY SEVERE AR W/IN 96 HRS FOLLOWING THE END OF FU OR CAPECITABINE ADMIN.
Regulatory Exclusivity Expiration:Sep 4, 2020
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Dec 11, 2018
Regulatory Exclusivity Use:NEW PRODUCT

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Johnson and Johnson
Merck
Medtronic
Cipla
Queensland Health
Colorcon
Citi
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.